Extended Platelet Rich Fibrin or Hyaluronate Enriched Xenografts for Horizontal Ridge Augmentation Via Subperiosteal Tunneling

NCT07412535 | Completed

• 1 other identifier: R.25.12.94
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

Extended platelet rich fibrin or hyaluronate enriched xenografts will be used for horizontal maxillary ridge augmentation via subperiosteal tunneling to allow placement of dental implants six months later.

Conditions

Dental Implant

Outcome Measures

Primary Outcomes (1)

• horizontal bone gain measurement

  CBCT will be used to measure horizontal bone width of the surgical site (in mm) at 3 points: at level of the crest, 2 mm and 6mm apical to the crest.

  6months, 12 months

Secondary Outcomes (1)

• bone density measurement

  6 months, 12 months

Study Arms (2)

Hyaluronate Group

ACTIVE COMPARATOR

Horizontal maxillary augmentation via subperiosteal tunneling using bovine bone and hyaluronate

Combination Product: bovine bone mixed with hyaluronate

Extended Platelet Rich Fibrin Group

EXPERIMENTAL

horizontal maxillary augmentation via subperiosteal tunneling using bovine bone and extended platelet rich fibrin

Combination Product: bovine bone mixed with E-PEF

Interventions

bovine bone mixed with hyaluronate COMBINATION_PRODUCT

cerabone plus will be inserted as a graft material via subperiosteal tunneling of thin maxilla

Hyaluronate Group

bovine bone mixed with E-PEF COMBINATION_PRODUCT

bovine bone mixed with E-PEF will be inserted as a graft material via subperiosteal tunneling of thin maxilla

Extended Platelet Rich Fibrin Group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• a maxillary anterior or premolar narrow ridge (width 3-6 mm), and adequate bone height (\>8 mm), seeking horizontal augmentation \& dental implant rehabilitation

You may not qualify if:

• systemic contraindications to surgery, local infection, untreated periodontal disease, heavy smoking, or pregnancy.

Sponsors & Collaborators

• Mansoura University: lead

Study Sites (1)

Mansoura University, Faculty of Dentistry

Al Mansurah, Egypt, 35516, Egypt

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: assistant professor of oral and maxillofacial surgery

Study Record Dates

• First Submitted: January 14, 2026
• First Posted: February 17, 2026
• Study Start: March 1, 2024
• Primary Completion: October 1, 2024
• Study Completion: October 1, 2025
• Last Updated: February 17, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will share

Locations

EG (1)